Antivirals for influenza-Like Illness? A randomised Controlled trial of Clinical and Cost effectiveness in primary CarE (ALIC4 E): the ALIC4 E protocol

BMJ Open

Volumn 8, Issue 7, 2018, Pages

  Bongard, Emily ^a   van der Velden, Alike W ^b   Cook, Johanna ^a   Saville, Ben ^c,d   Beutels, Philippe ^e   Aabenhus, Rune Munck ^f   Brugman, Curt ^b   Chlabicz, Slawomir ^g   Coenen, Samuel ^e   Colliers, Annelies ^e   Davies, Melanie ^h   De Paor, Muireann ⁱ   De Sutter, An ^j   Francis, Nick A ^k   Glinz, Dominik ^l,m   Godycki Ćwirko, Maciek ⁿ   Goossens, Herman ^e   Holmes, Jane ^a   Ieven, Margareta ^e   de Jong, Menno ^o   Lindbaek, Morten ^p   Little, Paul ^q   Martinón Torres, Frederico ^r   Moragas, Ana ^s   Pauer, József ^t   Pfeiferová, Markéta ^u   Radzeviciene Jurgute, Ruta ^v   Sundvall, Pär Daniel ^w,x   Torres, Antoni ^y   Touboul, Pia ^z,aa   Varthalis, Dionyssios ^ab   Verheij, Theo ^b   Butler, Christopher C ^a   more..

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c BERRY CONSULTANTS   (United States)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF ANTWERP   (Belgium)

^f UNIVERSITY OF COPENHAGEN   (Denmark)

^g MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^h Ely Bridge Surgery   (United Kingdom)

ⁱ ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^j GHENT UNIVERSITY   (Belgium)

^k CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^l UNIVERSITY OF BASEL   (Switzerland)

^m UNIVERSITY HOSPITAL BASEL   (Switzerland)

ⁿ MEDICAL UNIVERSITY OF LODZ   (Poland)

^o ACADEMIC MEDICAL CENTER   (Netherlands)

^p UNIVERSITY OF OSLO   (Norway)

^q UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^r University Hospital of Santiago de Compostela   (Spain)

^s UNIVERSITAT ROVIRA I VIRGILI   (Spain)

^t DRC Drug Research Center LLC   (Hungary)

^u CHARLES UNIVERSITY   (Czech Republic)

^v JSC Mano Seimos Gydytojas   (Lithuania)

^w Region Västra Götaland   (Sweden)

^x UNIVERSITY OF GOTHENBURG   (Sweden)

^y UNIVERSITY OF BARCELONA   (Spain)

^z UNIVERSITY HOSPITAL OF NICE   (France)

^aa UNIVERSITÉ CÔTE D'AZUR   (France)

^ab UNIVERSITY OF CRETE   (Greece)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; NON PRESCRIPTION DRUG; OSELTAMIVIR; PRESCRIPTION DRUG;

COMPLICATION; COST BENEFIT ANALYSIS; DAILY LIFE ACTIVITY; ECONOMICS; FEMALE; FEVER; HEADACHE; HOSPITALIZATION; HUMAN; INFLUENZA; MALE; MULTICENTER STUDY (TOPIC); MYALGIA; PNEUMONIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); SELF CARE; SYMPTOM ASSESSMENT; TIME FACTOR; VIROLOGY;

ACTIVITIES OF DAILY LIVING; ANTIVIRAL AGENTS; COST-BENEFIT ANALYSIS; FEMALE; FEVER; HEADACHE; HOSPITALIZATION; HUMANS; INFLUENZA, HUMAN; MALE; MULTICENTER STUDIES AS TOPIC; MYALGIA; NONPRESCRIPTION DRUGS; OSELTAMIVIR; PNEUMONIA; PRAGMATIC CLINICAL TRIALS AS TOPIC; PRESCRIPTION DRUGS; SELF CARE; SYMPTOM ASSESSMENT; TIME FACTORS;

EID: 85069287816     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/BMJOPEN-2017-021032     Document Type: Article

References (37)

1. Antonova EN, Rycroft CE, Ambrose CS, et al. Burden of paediatric influenza in Western Europe: a systematic review. BMC Public Health 2012;12:968.
2. World Health Organisation. Factsheet. http://www.who.int/mediacentre/factsheets/fs211/en/ (accessed 10 Aug 2017).
3. Centers for Disease Control and Prevention (CDC). Estimates of deaths associated with seasonal influenza - United States, 1976-2007. MMWR Morb Mortal Wkly Rep 2010;59:1057–62.
4. Schanzer DL, Langley JM, Tam TW. Co-morbidities associated with influenza-attributed mortality, 1994-2000, Canada. Vaccine 2008;26:4697–703.
5. Adriaenssens N, Coenen S, Kroes AC, et al. European Surveillance of Antimicrobial Consumption (ESAC): systemic antiviral use in Europe. J Antimicrob Chemother 2011;66:1897–905.
6. The National Institute for Health and Care Excellence. Amantadine, oseltamivir and zanamivir for the treatment of influenza. Technology appraisal guidance 2009;168 http://nice.org.uk/guidance/ta168.
7. Kramarz P, Monnet D, Nicoll A, et al. Use of oseltamivir in 12 European countries between 2002 and 2007–lack of association with the appearance of oseltamivir-resistant influenza A(H1N1) viruses. Euro Surveill 2009;14:19112.
8. Stephenson I, Clark TW, Pareek M. Antiviral treatment and prevention of seasonal influenza: a comparative review of recommendations in the European Union. J Clin Virol 2008;42:244–8.
9. Kmietowicz Z. WHO downgrades oseltamivir on drugs list after reviewing evidence. BMJ 2017;357:j2841 http://www.bmj.com/content/bmj/357/bmj.j2841.full.pdf.
10. World Health Organization. WHO model list of essential medicines 20th list, 2017. http://www.who.int/medicines/publications/ essentialmedicines/20th_EML2017_FINAL_amendedAug2017.pdf? ua=1 (accessed 08 Dec 2017).
11. McNicholl IR, McNicholl JJ. Neuraminidase inhibitors: zanamivir and oseltamivir. Ann Pharmacother 2001;35:57–70.
12. Roche Products Limited. SPC Tamiflu 30 mg, 45 mg and 75 mg Hard Capsules, 2017. https://www.medicines.org.uk/emc/medicine/20294 (accessed 10 Aug 2017).
13. Jefferson T, Jones MA, Doshi P, et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database Syst Rev 2014;4:Cd008965.
14. Jefferson T, Jones M, Doshi P, et al. Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ 2014;348:g2545.
15. Dobson J, Whitley RJ, Pocock S, et al. Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials. Lancet 2015;385:1729–37.
16. Okoli GN, Otete HE, Beck CR, et al. Use of neuraminidase inhibitors for rapid containment of influenza: a systematic review and meta-analysis of individual and household transmission studies. PLoS One 2014;9:e113633.
17. The Academy of Medical Sciences and Wellcome Trust. Use of neuraminidase inhibitors in influenza, October 2015. https://acmedsci.ac.uk/file-download/38069-561595082cd83.pdf (accessed 10 Aug 2017).
18. Abbasi K. The missing data that cost $20bn. BMJ 2014;348:g2695 http://www.bmj.com/content/bmj/348/bmj.g2695.full.pdf.
19. PREPARE Consortium. Platform for European Preparedness Against (Re-) emerging Epidemics. https://www.prepare-europe.eu/ (accessed 10 Aug 2017).
20. GRACE-LRTI Consortium. Genomics to combat Resistance against Antibiotics in Community-acquired LRTI in Europe. http://www.grace-lrti.org (accessed 10 Aug 2017).
21. Nuttall J, Hood K, Verheij TJ, et al. Building an international network for a primary care research program: reflections on challenges and solutions in the set-up and delivery of a prospective observational study of acute cough in 13 European countries. BMC Fam Pract 2011;12:78.
22. European Centre for Disease Prevention and Control. Seasonal Influenza Surveillance Reports. https://ecdc.europa.eu/en/seasonalinfluenza/surveillance-reports-and-disease-data (accessed 08 Dec 2017).
23. Official Journal of European Union. Commission implementing decision of 8 August 2012 amending Decision 2002/253/EC laying down case definitions for reporting communicable diseases to the Community network under Decision No 2119/98/EC of the European Parliament and of the Council (notified under document C(2012) 5538). 2012;16 http://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32012D0506&qid=1428573336660&from=EN#page=16.
24. Casalegno JS, Eibach D, Valette M, et al. Performance of influenza case definitions for influenza community surveillance: based on the French influenza surveillance network GROG, 2009-2014. Euro Surveill 2017;22.
25. Aguilera JF, Paget WJ, Mosnier A, et al. Heterogeneous case definitions used for the surveillance of influenza in Europe. Eur J Epidemiol 2003;18:751–4.
26. Berry DA. Bayesian clinical trials. Nat Rev Drug Discov 2006;5:27–36.
27. Krumholz HM. Neuraminidase inhibitors for influenza. BMJ 2014;348:g2548.
28. Thorpe KE, Zwarenstein M, Oxman AD, et al. A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers. J Clin Epidemiol 2009;62:464–75.
29. Little P, Williamson I, Warner G, et al. Open randomised trial of prescribing strategies in managing sore throat. BMJ 1997;314:722–7.
30. Little P, Rumsby K, Kelly J, et al. Information leaflet and antibiotic prescribing strategies for acute lower respiratory tract infection: a randomized controlled trial. JAMA 2005;293:3029–35.
31. Jacobs B, Young NL, Dick PT, et al. Canadian Acute Respiratory Illness and Flu Scale (CARIFS): development of a valid measure for childhood respiratory infections. J Clin Epidemiol 2000;53:793–9.
32. Berry SM, Connor JT, Lewis RJ. The platform trial: an efficient strategy for evaluating multiple treatments. JAMA 2015;313:1619–20.
33. Woodcock J, LaVange LM. Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both. N Engl J Med 2017;377:62–70.
34. Saville BR, Berry SM. Efficiencies of platform clinical trials: A vision of the future. Clin Trials 2016;13:358–66.
35. EuroQol Research Foundation. EuroQol EQ-5D. https://euroqol.org/euroqol/2017 (accessed 27 Nov 2017).
36. Ebell MH. WHO downgrades status of oseltamivir. BMJ 2017;358:j3266.
37. Fiore AE, Fry A, Shay D, et al. Antiviral agents for the treatment and chemoprophylaxis of influenza–recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011;60:1–24.